Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
  • [21] Recent advances of CCR5 antagonists
    Baba, Masanori
    CURRENT OPINION IN HIV AND AIDS, 2006, 1 (05) : 367 - 372
  • [22] Spiropiperidine CCR5 antagonists
    Rotstein, David M.
    Gabriel, Stephen D.
    Makra, Ferenc
    Filonova, Lubov
    Gleason, Shelley
    Brotherton-Pleiss, Christine
    Setti, Lina Q.
    Trejo-Martin, Alejandra
    Lee, Eun Kyung
    Sankuratri, Surya
    Ji, Changhua
    deRosier, Andre
    Dioszegi, Marianna
    Heilek, Gabrielle
    Jekle, Andreas
    Berry, Pamela
    Weller, Paul
    Mau, Cheng-I
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (18) : 5401 - 5406
  • [23] Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells
    Madan, Upasna
    Verma, Bhawna
    Awasthi, Amit
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 (07)
  • [24] Determination of nifeviroc, a novel CCR5 antagonist: Application to a pharmacokinetic study
    Wu, Wei
    Xie, Dong
    Cheng, Zeneng
    Liu, Zhi
    Ran, Liling
    Gu, Zhenkun
    Yu, Peng
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 56 (03) : 637 - 640
  • [25] Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc
    Lemoine, Remy C.
    Petersen, Ann C.
    Setti, Lina
    Baldinger, Thomas
    Wanner, Jutta
    Jekle, Andreas
    Heilek, Gabrielle
    deRosier, Andre
    Ji, Changhua
    Rotstein, David M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1674 - 1676
  • [26] A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc
    Jacqmin, Philippe
    McFadyen, Lynn
    Wade, Janet R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 : 95 - 106
  • [27] CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
    Pervaiz, Asim
    Ansari, Shariq
    Berger, Martin R.
    Adwan, Hassan
    MEDICAL ONCOLOGY, 2015, 32 (05)
  • [28] CCR5 Antagonists: a New Class of Antiretrovirals.
    Peytavin, Gilles
    Calvez, Vincent
    Katlama, Christine
    THERAPIE, 2009, 64 (01): : 9 - 16
  • [29] Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120
    Lisi, Lucia
    Tramutola, Antonella
    De Luca, Andrea
    Navarra, Pierluigi
    Dello Russo, Cinzia
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 (01) : 106 - 114
  • [30] HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism
    Roche, Michael
    Jakobsen, Martin R.
    Sterjovski, Jasminka
    Ellett, Anne
    Posta, Filippo
    Lee, Benhur
    Jubb, Becky
    Westby, Mike
    Lewin, Sharon R.
    Ramsland, Paul A.
    Churchill, Melissa J.
    Gorry, Paul R.
    JOURNAL OF VIROLOGY, 2011, 85 (09) : 4330 - 4342